Indivior Pharmaceuticals, Inc. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Indivior Pharmaceuticals, Inc. payments for repurchase of common stock for the quarter ending 2026-06-30 was $177.00M.
- Indivior Pharmaceuticals, Inc. payments for repurchase of common stock for the quarter ending 2026-03-31 was $125.00M, a 1036.36% increase year-over-year.
- Indivior Pharmaceuticals, Inc. payments for repurchase of common stock for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Indivior Pharmaceuticals, Inc. payments for repurchase of common stock for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Indivior Pharmaceuticals, Inc. payments for repurchase of common stock for fiscal 2025 was $11.00M, a 93.64% decline from fiscal 2024.
- Indivior Pharmaceuticals, Inc. payments for repurchase of common stock for fiscal 2024 was $173.00M, a 424.24% increase from fiscal 2023.
- Indivior Pharmaceuticals, Inc. payments for repurchase of common stock for fiscal 2023 was $33.00M, a 63.33% decline from fiscal 2022.
- Indivior Pharmaceuticals, Inc. payments for repurchase of common stock for fiscal 2022 was $90.00M.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $177.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $302.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $125.00M 10-Q · filed 2026-08-03 | $125.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.00M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $61.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $113.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $11.00M 10-Q · filed 2026-04-30 | $148.00M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $50.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $173.00M 10-K · filed 2026-02-26 |
| 2024-09-30 | $52.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | |
| 2024-06-30 | $35.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | |
| 2024-03-31 | $36.00M 10-Q · filed 2025-05-01 | |
| 2023-12-31 | $33.00M 10-K · filed 2026-02-26 | |
| 2022-12-31 | $90.00M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |